Abstract
The clinically relevant aspects of canine leishmaniasis are reviewed. Included are data from 92 dogs imported from the Mediterranean basin and at least 2 autochthonous cases. New aspects on pathogenesis are presented, including evidence that canine leishmaniasis is an immune complex disease. Therapy with meglumine antimonate (Glucantime®) is evaluated. The hazards of imported canine leishmaniasis for public health are discussed